Hemoglobinopathies Market Revenue to Hit USD 13,465.2 Million by 2026

Findings from the report entitled "Hemoglobinopathies Market by Indication (Sickle cell disease, Alpha Thalassemia, Beta Thalassemia, and Others), Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, and Others), Diagnosis (Blood testing, Genetic testing, Pre-implantation Genetic Diagnosis (PGD), and Other), and end-user (Hospitals, Diagnostic Laboratories, Clinics, and Other End It is estimated that the market will expand at a compound annual growth rate (CAGR) of over 10.34% and that it will reach over USD 13,465.2 Million by the year 2026.

𝐑𝐞𝐚𝐝 𝐃𝐞𝐭𝐚𝐢𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧@https://www.fnfresearch.com/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

The top key players operating in the market are

Alnylam Pharmaceuticals
bluebird bio Inc.
Celgene Corporation
Emmaus Life Sciences Inc.
Gamida Cell
Global Blood Therapeutics
Prolong Pharmaceuticals
Sangamo
Therapeutics Inc., and Sanofi

Hemoglobinopathies are brought on by both anemia and mutations in the patient's genes. The formation of default hemoglobin can occur under three different circumstances, including structural defects in the hemoglobin molecule, decreased production of one of the two subunits that make up the hemoglobin molecule, and abnormal interactions between subunits that would normally be considered safe. There is a spectrum of severity when it comes to illnesses. The most common diagnostic tools and tests for hemoglobinopathy and thalassemia are genetic diagnoses, genetic and blood testing, electrophoresis of alkaline and acid gel, hemoglobin electrophoresis, genetic prenatal testing, and chromatography exchange of ions HbA2.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚𝐧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @https://www.fnfresearch.com/sample/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

Improved R&D investments are projected to contribute to demand development for new therapies. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Health Institutes (NIH), is funding SCD research programs to find new methods of identifying and managing the disease and enhancing patient outcomes. New techniques are being developed using advances in gene-editing technology to modify or delete the faulty sickle cell disease gene and carry the restored gene back to the patients. Through support for sickle cell disease prevention and care through legislation such as the Sickle Cell Disease Research, Surveillance, Prevention, and Care Act, of 2018 is also likely to lead to better management of the situation.

The Hemoglobinopathies market is segmented into indication, therapy, diagnosis, end-user, and region segment. The indication segment is segmented into sickle cell disease, alpha-thalassemia, beta-thalassemia, and others. The therapy segment is divided into iron chelation therapy, blood transfusion, bone marrow transplant, and others. In 2018, blood transfusion therapy held the largest market share. Rising policy measures to increase the number of blood donors are a high impact-making engine for the demand for hemoglobinopathies.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭@https://www.fnfresearch.com/inquiry/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

The Diagnosis segment is bifurcated into blood testing, genetic testing, pre-implantation genetic diagnosis (PGD), and Others. In 2018, blood testing dominated the diagnosis segment in terms of revenue. The fact that blood testing is extensively used as the tool of first-line screening is a major contributor to its large market share. Due to its efficacy in precise diagnosis and monitoring, genetic testing for sickle cell disease diagnosis is projected to be the fastest-growing segment over the forecast timespan. The end-user segment is segmented into hospitals, diagnostic laboratories, clinics, and other end-user.

𝐍𝐞𝐞𝐝 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧? 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭@https://www.fnfresearch.com/customization/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

This report segments the Global Hemoglobinopathies Market as follows:

Global Hemoglobinopathies Market: Indication Segment Analysis

Sickle cell disease
Alpha Thalassemia
Beta Thalassemia
Others

Global Hemoglobinopathies Market: Therapy Segment Analysis

Blood Transfusion
Iron Chelation Therapy
Bone Marrow Transplant
Others

Global Hemoglobinopathies Market: Diagnosis Segment Analysis

Blood testing
Genetic testing
Pre-implantation Genetic Diagnosis (PGD)
Other

Global Hemoglobinopathies Market: End-user Segment Analysis

Hospitals
Diagnostic laboratories
Clinics
Other End-use

Global HemoglobinopathiesMarket: Regional Segmentation Analysis

North America
The U.S.
Canada
Europe
Germany
The UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of the Middle East & Africa

𝐑𝐞𝐚𝐝 𝐛𝐮𝐲𝐧𝐨𝐰 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧@https://www.fnfresearch.com/buynow/su/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: sales@fnfresearch.com
Web: https://www.fnfresearch.com

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client's/customer's conviction in our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

This release was published on openPR.